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Abstract
Background
There is increasing awareness that, aside from producing cerebrospinal fluid, the choroid
plexus (CP) might be a key regulator of immune activity in the central nervous system (CNS)
during neuroinflammation. Specifically, the CP has recently been posited to control entry of
sentinel T cells into the uninflamed CNS during the early stages of neuroinflammatory
diseases, like multiple sclerosis (MS) and its animal model experimental autoimmune
encephalomyelitis (EAE). As the CP is compartmentalized into a stromal core containing
fenestrated capillaries devoid of typical blood–brain barrier properties, surrounded by a tight
junction-expressing choroidal epithelium, each of these compartments might mount unique
responses that instigate the neuroinflammatory process.

Methods
To discern responses of the respective CP stromal capillary and choroidal epithelial tissues
during evolving neuroinflammation, we investigated morphology and in situ expression of 93

immune-related genes during early stages of EAE induced by immunization with myelin
oligodendrocyte glycoprotein peptide (MOG35-55). Specifically, 3-D immunofluorescent
imaging was employed to gauge morphological changes, and laser capture microdissection
was coupled to an Immune Panel TaqMan Low Density Array to detail alterations in gene
expression patterns at these separate CP sites on days 9 and 15 post-immunization (p.i.). To
resolve CP effects due to autoimmunity against MOG peptide, from those due to complete
Freund’s adjuvant (CFA) and pertussis toxin (PTX) included in the immunization, analysis
was performed on MOG-CFA/PTX-treated, CFA/PTX-treated, and naïve cohorts.

Results
The CP became swollen and displayed significant molecular changes in response to MOGCFA/PTX immunization. Both stromal capillary and choroidal epithelial tissues mounted
vigorous, yet different, changes in expression of numerous genes over the time course
analyzed - including those encoding adhesion molecules, cytokines, chemokines, statins,
interleukins, T cell activation markers, costimulatory molecules, cyclooxygenase, proinflammatory transcription factors and pro-apoptotic markers. Moreover, CFA/PTXtreatment, alone, resulted in extensive, though less robust, alterations in both CP
compartments.

Conclusions
MOG-CFA/PTX immunization significantly affects CP morphology and stimulates distinct
expression patterns of immune-related genes in CP stromal capillary and epithelial tissues
during evolving EAE. CFA/PTX treatment, alone, causes widespread gene alterations that
could prime the CP to unlock the CNS to T cell infiltration during neuroinflammatory
disease.

Keywords
Laser capture microdissection (LCM), Choroid plexus, EAE, Pertussis toxin,
Neuroinflammation

Introduction
Though the choroid plexus (CP) is commonly recognized as the production site of
cerebrospinal fluid (CSF) [1-3], it has relatively recently gained attention as a critical player
in central nervous system (CNS) inflammation [4-6]. Specifically, the CP has been suggested
as the site of entry into the uninflamed CNS of pioneer T cells searching for their cognate
antigens during immunosurveillance and in the early stages of neuroinflammatory diseases
such as multiple sclerosis (MS) and its animal model experimental autoimmune
encephalomyelitis (EAE) [7,8]. Current theory holds that, after crossing the CP into the CSF,
pioneer T cells travel to the subarachnoid space (SAS), where antigen-presenting cells
reactivate them. In turn, reactivation is thought to set off a burst of cytokines and other
mediators that inflames meningeal and parenchymal venules to initiate disease [9-11].
The anatomy of the CP appears well suited to orchestrating the initial steps of CNS
inflammation. It projects from the roofs of all four ventricles into the CSF, and is composed

of two distinct tissue layers: a highly vascularized stroma encapsulated by a “tight” layer of
epithelial cells [12]. Unlike the parenchymal capillaries forming the restrictive blood–brain
barrier (BBB), CP stromal capillaries are fenestrated and contain pentilaminar junctions
whose outer leaflets are not fused [13] – properties that render the CP capillary population
highly permeable to macromolecules [14]. This juxtaposition of “leaky” capillaries and tight
epithelium constitutes the blood-cerebrospinal fluid barrier (BSCFB) [15,16], an arrangement
construed as enabling blood-born leukocytes to extravasate into an uninflamed brain during
the incipient stages of MS and EAE [17,18]. Supporting this process, expression of
chemokine CCL20 by choroidal epithelial cells is thought to chemotactically draw T cells –
bearing the cognate receptor CCR6 – from the CP stroma, across the epithelium and into the
CSF [8].
In situ hybridization and immuno-electron microscopy of the CP has further revealed
expression of adhesion molecules, VCAM-1 and ICAM-1, by choroidal epithelial cells of the
healthy CP, and additionally of MAdCAM-1 by these same cells during EAE[19,20]. Also,
transcriptome analysis of the whole adult CP has highlighted expression of immune
mediators in both healthy mice [21] and those subject to peripheral inflammation [22],
reinforcing the view this organ is a critical conduit linking immune/inflammatory activities
between the periphery and CNS. But the extremely close apposition of the different CP layers
has posed a significant challenge to studying the depth of their respective contributions to
inflammatory processes. In fact, no immune function has yet been ascribed to the CP
capillary endothelium, leaving completely unresolved the factors that drive T cell emigration
into the stroma. And gene regulatory events surrounding transmigration of T cells across the
choroidal epithelium further remain unsettled.
To elaborate the sequence of events in the CP that set the stage for CNS inflammation during
EAE induced by active immunization with MOG35-55 peptide, we used laser capture
microdissection (LCM) coupled to qrt-PCR-based microarray [23] to establish the time
course of expression of a panorama of immune mediators in the separate stromal (including
capillaries) and choroid epithelial layers. Morphological changes in the CP associated with
MOG immunization were also examined by quantitative 3-D image analysis following
confocal microscopy. Results reveal substantial changes in CP gene expression and
morphology occurred in response to specific aspects of the MOG immunization process.
These results could hold relevance for how combinations of environmental factors trigger
neuroinflammatory disease.

Materials and Methods
Animals
Female C57BL/6 mice, age 8–10 weeks and obtained from Charles River Laboratories, Inc.
(Wilmington, MA), were used to minimize microvascular heterogeneity due to genetic
variability, sex, and age [24]. Animals were euthanized by CO2 inhalation, following Animal
Care and Use Guidelines of the University of Connecticut Health Center (Animal Welfare
Assurance # A3471-01). A total of n = 3 animals/group were used for each treatment and
time-point assessed.

Induction of experimental autoimmune encephalomyelitis (EAE)
EAE was induced in mice by active immunization with MOG35-55 peptide
(MEVGWYRSPFSRVVHLYRNGK), of murine origin (W. M. Keck Biotechnology
Resource Center, Yale University), as described [25]; following Animal Care and Use
Guidelines of the University of Connecticut Health Center (Animal Welfare Assurance #
A3471-01). Briefly, on day 0, one group of female mice 7–9 weeks of age was injected
subcutaneously with 300 μg of MOG peptide in complete Freund’s adjuvant (CFA, DIFCO)
into the right and left flank, 100 μl per site. These mice were also injected i.p. with 500 ng
pertussis toxin (PTX, List Laboratories, Campbell CA) in PBS on days 0 and 2 following the
first immunization (referred to as the MOG-CFA/PTX group). The second group of agematched mice received CFA alone and PTX (500 ng) injections on day 0 and a second
injection of 500 ng PTX alone on day 2 (referred to as the CFA/PTX group). The third group
of naïve age-matched female mice was left untreated. Animals were monitored and scored
daily for clinical disease severity according to the following scale: 0 = normal; 1 = tail
limpness; 2 = limp tail and weakness of hind legs; 3 = limp tail and complete paralysis hind
legs; 4 = limp tail, complete hind leg and partial front leg paralysis; and 5 = death. LCM tissue
was acquired at day 9 (score 0) and day 15 (score ~ 2.0) post-immunizations.

Tissue preparation for Immuno-LCM
Brains were snap-frozen in dry ice-cooled 2-methylbutane (Acros; Geel, Belgium), and
stored at −80 °C. Frozen brain was embedded in cryomatrix compound (Thermo Fisher
Scientific, Waltham, MA) prior to sectioning. Coronal sections (7 μm) were cut on a Microm
HM 505 M cryostat (Mikron Instruments; Oakland, NJ) and affixed to uncoated, pre-cleaned
glass slides (Fisher Scientific, Pittsburgh, PA) and stored in a slide box at −80 ° C. Tissue
was processed for LCM within a week of sectioning.

Immunostaining for Immuno-LCM
Immunostaining was performed as detailed [24,26,27], with minor modifications. Briefly,
sections were fixed in 75% ethanol, on ice, for 3 min prior to staining. The CP stromal
capillaries were stained using alkaline phosphatase substrate NBT (nitro-blue tetrazolium
chloride)/BCIP (5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt), (Vector Labs,
Burlingame, CA) for 3–5 minutes in 100 Mm Tris–HCl (pH 9.5) to detect endogenous
alkaline phosphatase activity in the endothelial cells. In this case, endothelial cells were
intentionally not immunostained by anti-CD31/ABC alkaline phosphatase [24,27], as it
resulted in extensive deposition of chromogenic precipitate, which made the stromal
capillaries difficult to resolve from the choroidal epithelial layer. The choroidal epithelial
cells were immunostained with monoclonal pan-cytokeratin-FITC antibody (Sigma) for 10
minutes (diluted 1:10 in 1X PBS + 0.5% Tween-20). RNAsin® RNAse inhibitor (Promega,
Madison, WI) was added to all staining reagents. Immediately after immunostaining, sections
were dehydrated through graded alcohol and xylenes as described [24].

Laser capture microdissection (LCM)
A PixCell IIe laser capture microscope (ABI, Foster City, CA) was used to separately procure
CP stromal capillary and CP choroidal epithelial tissues, as previously described for brain
parenchymal vessels [24,27,28]. We refer specifically to CP stromal capillary tissue, instead

of pure capillary endothelium, as it was not possible to completely resolve vascular from
matrix elements (including extravasating leukocytes) within the dense CP stroma. Likewise,
the choroidal epithelial tissue may contain some epiplexus cells, and so is not described as
pure epithelium. Only choroid plexus material from within the fourth ventricle and lateral
recess of the fourth ventricle was retrieved.

Tissue extraction
LCM-retrieved tissue was solubilized in Cell Lysate Buffer® (Signosis; Sunnyvale, CA) for
direct reverse transcription. Cell Lysate Buffer®, pre-heated to 75 °C, was added and the
resulting lysate heated at 75 °C for an additional 15 min. Samples were immediately frozen at
−80 °C.

DNase treatment and cDNA synthesis
Cell Lysate Buffer® extracts were treated with Turbo DNase (Ambion; Austin, TX)
according to the manufacturer’s instructions. Specifically, Turbo DNase buffer and DNase
were added and samples incubated at 37 °C for 30 min. Next, DNAse inactivation reagent
was added for 2 min at room temperature. Samples were then reverse transcribed using the
SuperScript III (Invitrogen) standard protocol with random hexamers (Roche; Indianapolis,
IN), and employing an extension temperature of 42 °C – optimal for random hexamers – for
60 min. Resulting cDNA was stored at −20 °C until used for analysis.

cDNA Pre-Amplification
Pre-amplification was carried for array analysis out using TaqMan® PreAmp Master Mix and
a PreAmp Pool containing all the primers for detection by the Mouse Immune Panel
TaqMan® Low density Array (TLDA; Life Technologies Corp., Foster City, CA) [23]. This
panel conatins 93 immune-related genes plus three housekeeping control genes (see
Additional file 1: Mouse Immune Panel TLDA). Pre-amplification was carried out with an
initial hold at 95 °C for 10 min, followed by 14 cycles at 95 °C for 15 sec and 60 °C for 4
min.

qrt-PCR
Relative cDNA levels were quantified by qrt-PCR using an ABI PRISM 7500 Sequence
Detection System Version 2.3, and reported compared to housekeeping gene GAPDH.
Relative quantitation to GAPDH was performed using the standard 2–δCt method of Pfaffl
[29], where δCt = Ct target threshold cycle – Ct reference (GAPDH) threshold cycle.
Expression of genes relative to GAPDH was then represented as percent expression of
GAPDH. To assure consistency in relating gene expression patterns to a housekeeping gene,
GAPDH and two other housekeeping genes, β-actin and 18 S ribosomal RNA, were
evaluated for constant expression across treatments. Additionally, gene expression values for
a handful of randomly selected immune-related genes were also determined relative to β-actin
and 18 S ribosomal RNA (see Additional file 2: Housekeeping control genes). Custom
TaqMan® primers/probes were used for the Mouse Immune Panel TLDA. TLDA analysis
was conducted as per the manufacturer’s protocol, with 100 μl sample volumes containing a
1/32 dilution of pre-amplified cDNA added to each port of the microfluidic card [23]. For

qrt-PCR analysis of CD31 and Cytokeratin 8, ‘singleplex’ assays were used as neither of
these genes are represented in the mouse Immune Panel TLDA.

Immunostaining for confocal microscopy
Frozen cryosections (60 μm) were fixed with 4% paraformaldehyde, permeabilized with 1%
Triton X-100 (in PBS) and incubated with Powerblock® for 10 min. Purified rat anti-mouse
CD31 antibody (BD Pharmingen; 1:150 dilution in 10% NBS in 1X PBS + 0.5% TW-20) was
used to stain the CP capillary network followed by incubation with goat anti-rat Alexa-555
secondary antibody (1:200). Pan-cytokeratin-FITC 1: 150 dilution, (Sigma) was used to stain
the CP epithelium. Next, Alexa-647 anti-mouse CD45 antibody (1:160 dilution) was used to
stain leukocytes.

Confocal microscopy
Images were acquired on a Zeiss LSM 510 Meta laser scanning confocal microscope, and
optical slices (at 2-μm intervals) obtained using a 40x objective. Acquired z-stacks were
background-subtracted, and 3-D isosurface rendering performed using Bitplane IMARIS
suite version 7.1 x 64 software (Bitplane Inc. Saint Paul, MN). Each z-stack was thresholded
and the “filament tracker” module used to generate a 3-D traced outline of immunostained
vessels in order to determine the diameter range of the CD31-immunostained capillary
network within the choroid plexus across different treatments.

Statistical analysis
Relative gene expression values are given as mean ± SEM. Student’s two-tailed test
(Microsoft Excel 2003, Redmond, WA) was employed to assess statistical significance in
gene expression values between MOG-CFA/PTX and CFA/PTX samples from the CP
capillary stroma and CP epithelium groups, separately for the two different time points
assessed. Results were considered significant at a p ≤ 0.05. Additionally, two-way ANOVA
followed by post-hoc Bonferroni analysis was performed using GraphPad Prism 5
(GraphPad, La Jolla, CA) to determine interactive effects between immunization treatment
and time of analysis post-immunization, and assessed for each CP compartment.

Results
Anatomy of the CP is altered in response to MOG-immunization
First, the anatomy of the CP was investigated using confocal microscopy followed by 3-D
isosurface rendering. The close apposition of stromal capillary and choroidal epithelial layers
in the CP is depicted in Figure 1. The 3-D analysis highlights the tortuosity of the capillary
plexus. At day 15 post immunization (p.i.) with PTX and MOG35-55 peptide in CFA to induce
EAE (MOG-CFA/PTX group), or with PTX and CFA alone (CFA/PTX group), which does
not produce disease in this paradigm, the capillary plexus can be seen to locally ‘swell’ in
certain regions (Figure 1). Specifically, the range in diameter of capillaries in the MOGCFA/PTX and CFA/PTX groups was 1.24 to 11.39 μm and 1.86 to 10.84 μm respectively, as
compared to that found in naïve (1.24 to 6.22 μm) mice. In contrast to that seen within CP
capillaries, the morphology of the choroidal epithelial layer remained relatively constant
following immunization.

Figure 1 Morphological analysis of CP compartments following immunization. CP
epithelium was stained with polyclonal antibody to pan-cytokeratin (FITC, green), and CP
stromal capillaries were immunostained with monoclonal anti-CD31 antibody (red). A CD45
antibody was used to stain for any leukocytes present within the CP (blue). Confocal
microscopy z-stack images of thick (60 μm) frozen sections of the CP were acquired, and
three dimensional rendering was performed using Imaris image analysis software. Shown are
rendered images of the CP from all three treatment conditions (MOG-CFA/PTX day 15 p.i.,
CFA-PTX day 15 p.i. and Naïve), revealing swelling of the stromal capillaries (arrows)
following both immunization protocols. The left side shows leukocyte and capillary staining,
emphasizing the distended capillary diameters. The right side is a composite of leukocyte,
capillary, and epithelial staining. Mean capillary diameter ranges for each group were
determined using the Filament tracer module in Imaris. The choroidal epithelium appears
unaltered by immunization. ‘p’ indicates brain parenchymal region. Scale: 20 μm

LCM enables resolution of CP stromal capillaries from the choroidal
epithelium
Studies were next carried out to confirm the ability of LCM to resolve the stromal capillary
and choroidal epithelial layers. Figure 2A shows an example of the highly selective retrieval
of both tissues from naïve and EAE brain specimens. Microscopic analysis indicates no
appearance of fluorescently-stained choroidal epithelial tissue in the LCM-captured
capillaries and, conversely, no alkaline phosphatase-stained capillary tissue in the retrieved
epithelial samples. Figure 2B further highlights the purity in qrt-PCR detection of LCM tissue
from the respective CP compartments. Using equivalent amounts of input LCM tissue (1000
laser ‘shots’) from both CP compartments, the endothelial marker CD31 was significantly
enriched in the CP capillary tissue, while the epithelial marker cytokeratin 8 was observed in
CP epithelial tissue alone. The extremely low level of CD31 mRNA detected in CP epithelial
tissue may reflect the few monocytes and/or dendritic cells circulating through this area in the
steady-state mouse brain [29,30]. There is thus high confidence that LCM effectively
separates CP stromal capillary from choroidal epithelial layers with high purity.
Figure 2 Immuno-LCM allows retrieval of tissue from specific CP compartments. A)
Evidence of histological purity. Immunofluorescence was performed using FITC-conjugated
pan-cytokeratin antibody to highlight the CP epithelium (green), while
immunohistochemistry using alkaline phosphatase detection with NBT/BCIP as substrate was
carried-out to label the endothelium of CP stromal capillaries (dark brown). LCM was
performed on a Pixcell IIe LCM unit. Images both BEFORE and AFTER LCM, as well as
LCM retrieved tissue deposited on the cap, are shown to highlight selective retrieval of CP
stromal capillary (top row) and CP choroidal epithelial tissues (bottom row). B) Evidence of
purity by qrt-PCR. Levels of CD31, an endothelial marker, and Cytokeratin-8, an epithelial
marker, were probed to determine the purity of the CP capillary and CP epithelial tissues,
respectively, retrieved by LCM

Expression of immune-related genes by stromal CP capillary tissue following
immunization
The next series of experiments coupled LCM to TLDA qrt-PCR arrays to further characterize
expression patterns of a panorama of 93 immune-related genes in the separate CP
compartments at different stages of the neuroinflammatory response to immunization.

Expression of these genes relative to housekeeping gene GAPDH (GAPDH was unaffected
across treatments; Additional file 2: Housekeeping control genes), was determined in three
groups of mice: MOG-CFA/PTX, CFA/PTX and naïve at two time points: day 9 and 15 p.i.
Contrasting these three treatment groups enabled effects of the adjuvants CFA and PTX to be
distinguished from the autoimmune response to MOG. Furthermore, examining effects at day
9 p.i. (prior to any evidence of clinical disease) and day 15 p.i. (after disease onset),
highlighted the progression of gene changes that may be linked with developing pathology.
At day 9 p.i. (EAE clinical score 0), numerous gene changes were already evident in the CP
stromal capillary tissue, despite the lack of onset of any clinical disease signs. Specifically,
both MOG-CFA/PTX- and CFA/PTX-immunized mice showed up-regulated expression in
49 of the genes in the panel compared to naïve animals, (Table 1), with there being no
statistically significant differences between the two immunized groups. Some prominent
inflammatory genes that were equivalently elevated at this time point included: CCL2, CCL5,
CXCL10, Sele (E-selectin), Selp (P-selectin), IL1b, Stat1 and Fasl all of which were
modulated more than 10 fold higher than naïve levels. It would thus appear that, at this early
stage before clinical EAE symptoms are present, the gene responses in the CP stromal
capillary tissue following MOG immunization may stem largely from adjuvants CFA and/or
PTX.
Table 1 Genes similarly up-regulated in CP stromal capillary tissue from both MOGCFA/PTX- and CFA-PTX-immunized mice at day 9 p.i
Genes modulated similarly in stromal CP capillary of MOG-CFA/PTX mice at day 9 p.i
Gene name
Gene name
‡
B2m
ll15*
Bcl2l1
ll18*
‡
C3**
ll1b**
‡
Ccl19
ll7
Ccl2**
Lrp2
‡
Ccl5**
Nfkb1*
Ccr2**
Nfkb2
Cd34**
Ptgs*‡
Cd80
Sele**
Cd86*
Selp**
Cd8a
Amad3‡
Col4a5
Socs2
Csf1*
Stat1**
Cxcl10**
Stat3
Cxcr3*
Stat4‡
Ece1
Stat6
Edn1
Tbx21
Fas
Tfrc*
Fn1
Tgfb1
‡
Gzmb
Cd40
Hmox1
Fasl**
Hprt1
Vcam1

lcos
Vegfa
lfng**
genes with * ≥ 5 and ** ≥ 10 fold increase in expression in comparison to Naïve animals
Relative mRNA expression values of 93 immune-related genes were determined by immunoLCM/TLDA in CP stromal capillary tissue from immunized and naïve mice at day 9 p.i. At
this early time-point, all 49 immunization-induced genes were similarly stimulated in both
MOG-CFA/PTX- and CFA-PTX-immunized mice compared to naïve animals, and only these
are listed. ‡ denotes genes that show specific upregulation later on with disease progression
on day 15
By day 15 p.i. (EAE clinical score 1.5-2.0), however, the MOG-CFA/PTX-immunized group
surpassed the CFA/PTX group in up-regulation of several genes, highlighting what might
specifically be the autoimmune response of the CP vascular stroma. These genes included
B2m, C3, CCL19, CCL5, CD4, Gzmb, Ptgs2, Ptprc (CD45), Smad3, Stat4, and CD40l –
which were selectively augmented in the CP stromal capillary tissue of the MOG-CFA/PTX
group (Figure 3). The fold changes in these genes following immunization (Figure 3, bottom)
indicate their super-stimulation by MOG-CFA/PTX treatment. The lymphoid chemokine
CCL19, expressed by venules in brain and spinal cord in mice afflicted with EAE [31], was
elevated nearly 80-fold in the MOG-CFA/PTX immunized mice at this time-point. And
CCL5, another chemokine shown to play an important role in EAE [32], was elevated 146fold higher than naïve levels. Expression of Ptgs2 (COX2), suppression of which has been
associated with resistance to EAE [33,34], was near similarly elevated – having increased 96fold higher than that in naïve cohorts. Slightly less elevated was Stat4, a transcription factor
whose absence has been shown to inhibit EAE [35], which was increased > 40-fold in the
MOG immunized group. It is further noteworthy that expression of Ptprc (CD45), the
common leukocyte marker, stimulated 219-fold higher, possibly reflecting increased
leukocyte extravasation across the stromal capillaries at this later time-point. Consistent with
this interpretation is that message for CD40l (CD154), a protein primarily expressed on
activated T cells [36], was detected within the CP stromal capillary tissue only following
MOG-CFA/PTX immunization.
Figure 3 Genes super-induced in CP stromal capillary tissue from MOG-CFA/PTXimmunized mice at day 15 p.i. Relative mRNA expression values were determined by
immuno-LCM/TLDA in CP stromal capillary tissue from MOG-CFA/PTX-immunized,
CFA-PTX-immunized, and naïve mice at day 15 p.i. Those genes that were more stimulated;
i.e., ‘super-induced’, in MOG-CFA/PTX- versus CFA-PTX-immunized mice at day 15 p.i.
(compared to naïve mice) are graphed. The bar graphs depict those specific genes showing
statistically significant differences in relative expression values (p values indicated by
asterisks) between MOG-CFA/PTX and CFA/PTX experimental groups. RNA values are
presented as mean percent expression relative to GAPDH (± SEM) in log scale. * and **
represent comparisons made between MOG-CFA/PTX and CFA-PTX- treatment groups, *
p < 0.05, ** p < 0.005, Student’s t-test, n = 3 animals/group. Fold changes in gene expression
normalized to naïve animals are tabulated below the graph. Fold changes of those genes that
were up-regulated after immunizations but undetectable in naïve are denoted as ‘∞’
Notably, the CFA/PTX group indicated some dampening of immune regulation by this time,
as certain genes e.g.., Smad3 and Gzmb, dropped back to levels matching those of naïve
mice, after initially displaying an elevation at day 9. Genes that trended towards elevated
expression following MOG-CFA/PTX treatment (but with p values slightly > 0.05) are

displayed in Additional file 3: Genes that trended towards elevated expression in MOGCFA/PTX- immunized CP stromal capillary tissue compared to CFA-PTX-immunized mice,
at day 15 p.i, while those that were similarly up-regulated in CP stromal capillary tissue of
MOG-CFA/PTX- and CFA/PTX-immunized mice compared to naïve mice at day 15 are
listed in Additional file 4: Genes similarly up-regulated in CP stromal capillary tissue from
both MOG-CFA/PTX- and CFA-PTX-immunized mice at day 15 p.i. Genes that were
undetected in the CP capillary tissue in all treated and naïve mice at both time-points were the
following: CCR4, CD19, CD3e, CSF3, Ctla4, Cyp1a2, Cyp7a1, H2-Ea, IL12b, IL13, IL3,
IL4, IL5, IL6, IL9, and Lta.

Expression of immune-related genes by CP choroidal epithelium following
immunization
Immunization also produced a change in expression of numerous immune-related genes
within the CP choroidal epithelium. Moreover, these changes differed from those observed in
the capillary stroma, emphasizing the differential immune sensitivities of the two tissues.
At day 9 p.i., the CP choroidal epithelium of only MOG-CFA/PTX-immunized mice
displayed increased expression of any immune-related genes compared to that of naïve
cohorts. Specifically, the following eight immune-related genes were up-regulated: B2m,
CCL19, CCL2, CCR2, CD8a, CXCL10, Sele, and Selp (Figure 4 A). B2m (beta 2
microglobulin), a biomarker for certain peripheral inflammatory conditions [37] was
increased 2.2-fold in MOG-treated versus naïve mice. The chemokine CCL2 has been
demonstrated to play a critical, non-redundant role in directing mononuclear leukocyte
extravasation into the CNS during EAE [32,38,39], and was stimulated > 24-fold higher in the
CP choroidal epithelial tissue of MOG-CFA/PTX-treated mice compared to that in naïve
cohorts. CXCL10 and CCL19 were 28-and 14-fold higher than naïve values, respectively.
Sele (E-selectin) and Selp (P-selectin), CCL19 and CD8a further showed pronounced
stimulation specifically following MOG immunization, being undetectable in the epithelium
of both CFA/PTX and naïve cohorts. In what appears to reflect the differential sensitivities of
the two CP tissues, CFA/PTX immunization clearly ‘activated’ the stromal CP capillary
tissue on day 9 p.i. at both the anatomical and molecular levels (Figure 1b and Table 1), but
produced no detectable changes in the CP epithelium at this time.
Figure 4 Genes super-induced in CP choroidal epithelial tissue from MOG-CFA/PTXimmunized mice at days 9 and 15 p.i. Relative mRNA expression values of 93 immunerelated genes were determined by immuno-LCM/TLDA in CP choroidal epithelial tissue
from MOG-CFA/PTX-immunized, CFA-PTX-immunized, and naïve mice at two timepoints. Those genes that were more stimulated in MOG-CFA/PTX- versus CFA-PTXimmunized mice at day 9 (Figure 4A) and day 15 p.i (Figure 4B) (compared to naïve mice)
are graphed. The bar graphs depict those specific genes showing statistically significant
differences in relative expression values (p values indicated by asterisks) between MOGCFA/PTX and CFA/PTX experimental groups. RNA values are presented as mean percent
expression relative to GAPDH (± SEM) in log scale. * and ** represent comparisons made
between MOG-CFA/PTX and CFA-PTX- treatment groups, * p < 0.05, ** p < 0.005,
Student’s t-test, n = 3 animals/group. Fold changes in gene expression normalized to naïve
animals are tabulated below the corresponding graphs. Fold changes of those genes that were
up-regulated after immunizations but undetectable in naïve are denoted as ‘∞’

By day 15 p.i., genes B2m and CXCL10 displayed further increases in expression in the CP
choroidal epithelium of MOG-CFA/PTX mice compared to that seen in this cohort at day 9
(Figure 4B), showing > 19-fold and > 800-fold higher levels, respectively, compared to naïve
mice. Expression levels of yet additional genes in MOG-treated mice also became elevated
by this time; these included Bax, Bcl2l1, C3, CD68, Gusb, H2-Eb1 and Ski (Figure 4B).
Moreover, genes CCL19, CCL2, CCR2, CD8a, Sele and Selp, which had previously shown
up-regulation only in the MOG-CFA/PTX group at day 9, became similarly induced in the
CFA/PTX group at this later time-point. Genes that trended towards elevated expression
following MOG-CFA/PTX treatment for both time points (but with p values slightly >0.05)
are displayed in Additional file 5 and Additional file 6: Genes that trended towards elevated
expression in MOG-CFA/PTX immunized CP epithelium tissue compared to CFA-PTXimmunized mice, at day 9/15p.i., while those that were similarly up-regulated in CP choroidal
epithelial tissue of MOG-CFA/PTX- and CFA/PTX-immunized mice compared to naïve mice
for both time points are listed in Additional file 7 and Additional file 8: Genes similarly upregulated in CP epithelium from both MOG-CFA/PTX- and CFA-PTX-immunized mice at
day 9/15 p.i. Those few genes that were in the CP epithelial tissue in both immunized groups
and naïve mice included IL3, IL4, IL5, IL6, Lta.

Interaction between immunization treatment and time
In order to gain further appreciation of the extent to which time impacted the effect of
specific type immunization on the expression patterns of immune-related genes, two-way
ANOVA was performed to deduce interactive effects between immunization treatment (e.g.,
MOG-CFA/PTX, CFA/PTX or naïve) and time post-immunization. For example, the
expression of CCL19 in CP stromal capillary tissue following MOG-CFA/PTX immunization
was time-dependent (p < 0.05 for positive interaction). Two-way ANOVA was done on all
genes that displayed statistically significant modulation after immunization in at least one of
the CP compartments (as shown in Figures 3 and 4A, B) in either of the time-points analyzed
(twenty-three genes in total). Interactive effects differed depending on the CP compartment,
further highlighting the unique responses of the two CP tissues analyzed. Specifically, twoway ANOVA of CP stromal capillary tissue revealed the following twelve genes displayed
positive interaction between immunization treatment and time post-immunization: B2m, C3,
CCL19, CCL5, CD4, Gzmb, Ptgs2, Ptprc, Stat4, CCR2, CD68, Gusb (Figure 5). CP
choroidal epithelial tissue, on the other hand, demonstrated positive interaction for another
collective of genes: B2m, Bax, C3, CXCL10 (Figure 5).
Figure 5 Interaction between immunization treatment and time of analysis postimmunization on expression of immune-related genes within CP stromal capillary and
choroidal epithelial compartments. Interactive effects of treatment (MOG-CFA/PTX, CFAPTX and naïve) and time post-immunization were determined by two-way ANOVA on the
23 immune-related genes that were super-induced following MOG-CFA/PTX immunization
in either of the two CP compartments (those genes graphed in Figures 3, 4A and B). Of these
23 genes, 13 genes in the CP stromal capillary and 4 genes in the CP epithelial tissue
exhibited significant positive interaction between treatment and time post-immunization, and
are denoted with their corresponding p values. The remaining genes that showed no
significant interaction are labeled by (x). Time-dependent changes in expression of CCL19 in
stromal capillary tissue and CXCL10 in choroidal epithelial tissue are graphed as
representative examples * p < 0.05, ** p < 0.005

Figure 6 qualitatively summarizes the differential responses of the CP capillary and CP
choroidal epithelial tissues, respectively, to MOG-CFA/PTX immunization versus CFA/PTX
immunization, contrasting adjuvant versus autoimmune effects on immune-related gene
regulation over the two time-points analyzed.
Figure 6 Schematic summary of the induction of immune-related genes in the choroid
plexus compartments following MOG-CFA/PTX versus CFA-PTX immunization.
Depicted are qualitative ‘heat maps’ of overall modulation in immune-related gene
expression patterns over time, within the separate CP stromal capillary (left) and CP
choroidal epithelial (right) tissues after the two type immunization regimens. While
CFA/PTX immunization alone induces expression of immune-related genes in both tissues,
MOG-CFA/PTX immunization causes supernumerary stimulation above this level. The
differences in gene expression between the immunization regimens highlight what might
reflect gene changes specifically due to MOG-associated autoimmunity. The effects due
solely to CFA/PTX immunization might reveal priming of the immune response that is
necessary for the development of EAE

Discussion
Due to increasing awareness of the CP as fundamental to the development of CNS
inflammation [4-6], immuno-LCM coupled to qrt-PCR array was used to separately acquire
CP stromal capillary and choroidal epithelial tissues and assess their respective patterns of
expression in situ of a wide panorama of immune-related genes. Gene patterns were
evaluated during preclinical and early clinical stages of EAE to appreciate the switches in
gene expression that accompany evolving disease.
It is clear that the CP responds vigorously to MOG immunization at both the anatomical and
molecular levels. Interestingly, immunization with CFA and PTX alone produced striking
effects. Swelling of the capillary plexus occurred to nearly the same extent with injection of
just these agents, as with PTX and MOG in CFA. PTX is an ancillary adjuvant commonly
employed to elicit EAE, as well as several other experimental autoimmune diseases [40-44].
And while its mechanism of action in this regard has generally been attributed to increasing
vascular permeability [45-47] – most notably that of the BBB [48-51] – additional hypotheses
have been put forth [52-55]. However, to the best of our knowledge, this is the first report to
turn attention to the CP as a possible target of PTX. It is of further interest to point out that
the distension of CP capillaries noted here study bears similarity to that seen following
systemic neutralization of VEGF and TGFβ [56]. In the latter case, CP capillary swelling was
accompanied by loss of fenestrae from endothelial cells and appearance of multiple caveolae,
transport vesicles that transcytose a variety of cargo [57] – including chemokines [58] – and
are often associated with heightened vascular permeability and inflammation [59,60].
Engelhardt et al. [4] had also described ultrastructural changes of the CP during EAE (along
with CFA and PTX as adjuvants), but noted these were mostly restricted to the CP choroidal
epithelium. Moreover, as comparison in this latter study was just between healthy mice and
those afflicted with EAE, it is unclear whether the observed epithelial response was
autoimmune in nature and/or due to adjuvant action.
Our results suggest that injection of PTX and/or CFA, alone, might trigger an immune
response in the CP capillaries that helps “set the stage” for CNS inflammation [61]. The CP
capillaries might be uniquely responsive in this regard, as CFA/PTX treatment evoked an

early response (day 9 p.i.) in the CP stromal capillary tissue, while the choroidal epithelium
experienced neither overt morphological nor gene expression changes at this time. If, as
speculated during MS/EAE, Th17 cells first transit through the CP, and then travel in the CSF
to reach their cognate antigens in the SAS, then the CP capillaries must somehow initially be
rendered capable of supporting T cell extravasation. In the EAE paradigm used here, PTX
and/or CFA might provide the stimulus to evoke such capability. In this regard, we
noted > 10-fold increase in chemokines CCL2, CCL5 and CXCL10 in the CP stromal
capillaries of both MOG-CFA/PTX- and CFA/PTX-treated mice at day 9 p.i. Constitutive
CCL2 expression within the CP stromal tissue has been reported using in situ hybridization
analysis, and shown to be induced following peripheral tissue inflammation [62]. The ability
of CFA/PTX treatment to stimulate expression of these chemokines could potentially reflect
the actions of one or both of these adjuvants to ‘prime’ the neuroinflammatory process by
activating the endothelium to elicit initial auto reactive T cell extravasation from the
circulation into the stromal compartment. This hypothesis is consistent with the recent
observation that administration of PTX to transgenic mice over-expressing CCL2 in the CNS
causes disruption of the BBB and promotes leukocyte migration into the brain parenchyma
[63].
Notwithstanding the effects of CFA/PTX treatment on CP capillary morphology and gene
expression, immunization with MOG-CFA/PTX further induced the expression of additional
genes – some or all of which might specifically reflect the autoimmune response and
associated development of EAE. While perhaps necessary for disease to develop, the CP
conditions set in place by PTX and CFA are insufficient for inducing EAE in wild-type
C57BL/6 mice. For disease to occur, supernumerary induction of some genes, and de novo
induction of others must take place. The findings by Goverman et al. and Brabb et al. [61,64],
that injection of PTX alone can “trigger” EAE in TCR-transgenic mice specific for myelin
basic protein, by fostering T cell access to the CNS, comports with our results and the view
that PTX enables mice to reach the disease threshold. And helping pull this trigger may be
additional effects of PTX on T cell behavior. Our observation of increased mRNA for genes
CD8a, CD80, CD86, Gzmb (granzyme) and Ptprc (CD45) in the CP capillary stromal tissue
of both MOG-CFA/PTX and CFA/PTX cohorts may reflect capture of PTX-activated CD8 T
cells in transit across the CP and into the CSF. This interpretation is consistent with the recent
finding by Murphey et al. [65], that PTX stimulation of cultured spleen cells results in CD 8
T cell activation via CD80/86 co-stimulation.
As to signals responsible for the extravasation of T cells from the circulation into the CP
stroma during MOG-induced EAE, a combination of chemokines may fill this role, as these
immune mediators do in guiding parenchymal leukocyte infiltration. In particular, CCL5
level was increased significantly in CP stromal capillary tissue at day 15 p.i., which coincides
with high CCL5 protein level reported in whole brain extract of EAE mice at a similar timepoint, and argued to mediate leukocyte adherence to the CNS microvasculature [32]. And
CCL19 – a CCR7 ligand known to play a crucial role in EAE development through IL-23
producing Th17 cells [66] – was likewise up-regulated dramatically in the CP stromal
capillaries of MOG immunized mice at day 15 p.i.
With specific regard to those mechanism(s) further driving T cell migration from the CP
stroma into the CSF, recent evidence points toward expression of another chemokine CCL20 - by the CP choroidal epithelium as directing CCR6+ T cells across this layer and into
ventricular fluid during MS/EAE [8]. However, as this chemokine:cognate receptor pair was
not represented on the commercial TLDA card used in these experiments, confirmation of

this pathway was not performed. Aside from CCL20 providing a driving force for T cell
migration into CP epithelium, CCL2 might also serve in this capacity, as Chodobska et al.
[67] noted the latter chemokine was rapidly stimulated in this tissue in vivo and then released
into the CSF, following traumatic brain injury. Indeed, the significant increase in CCL2 we
observed in the MOG-CFA/PTX CP choroidal epithelium at day 9 p.i. might just reflect such
a role for this chemokine in EAE. The cognate receptor for CCL2, CCR2 was also seen to be
elevated in the choroidal epithelium at this early time-point. Presently, it is unclear if the high
levels of CCR2 mRNA indicate activation of the epithelium, which, in the periphery, has
been shown to express CCR2 [68,69], or the accumulation of infiltrating CCR2+ T cells.
In what might suggest multi-level control of leukocyte extravasation into the CSF, still other
chemokines were also significantly up-regulated by the CP during EAE – namely CXCL10
and CCL19. As CXCL10 has been reported to be up-regulated in the sub-ventricular zone
(SVZ) during EAE, and postulated to stimulate migration of activated T cells into the SVZ
[70], its spike in expression by CP choroidal epithelial tissue at day 9 p.i. and more robust
elevation by day 15 p.i., might imply this chemokine is obligate for T cell entry into the
ventricles. In analogous manner, CCL19 was also elevated at this site at day 9 p.i. In fact, the
timing of the CP epithelial spikes in this chemokine during early stages of EAE noted here,
coincides well with that reported by Reboldi et al. [8] for initial T cell entry into the
uninflamed CNS through the CP. Recently, Marques et al. [22,71] used hybridization-based
microarray to assess the global transcriptome of the whole CP following chronic peripheral
LPS stimulation. When compared to our study, there were some common and unique
findings. Among the common findings, complement protein C3, and chemokines CCL2 and
CCL5 were elevated following either acute or chronic peripheral LPS stimulation, as well as
during MOG-induced EAE (complement C3 in both CP capillary tissue and epithelium;
CCL2 in CP epithelium; and CCL5 in CP capillary tissue). And Selectin (Sele and Selp)
expression was also elevated both following acute peripheral LPS stimulation [22], and in the
CP epithelium after MOG-induced EAE. These common gene modulations may thus reflect
more generic CP inflammatory response genes. As for unique findings, these too involved
chemokines. Marques et al. [71] reported stimulation of CCL7 and CXCL1 in the CP
following chronic LPS stimulation, while we detected stimulation of CCL19 and CXCL10 in
the CP epithelium and CCL19 in the CP endothelium during MOG-induced EAE. A priori,
up-regulation of these latter two chemokine genes may more distinguish an EAE signature
for the respective CP tissue compartments.
Of further note was our observation of a MOG-sensitive increase in expression of B2m at day
15 p.i. in CP stromal capillary tissue, and at both time-points in the choroidal epithelial tissue.
Aside from perhaps reinforcing a more ubiquitous role for B2m in inflammation [37], this
result complements previous reports of increased B2m mRNA and protein levels in both
neuronal and non neuronal cell types during EAE [72,73], a response thought to be due to
induction of synaptic plasticity by infiltrating autoreactive immune cells. The sharp induction
of complement C3, also noted in both CP compartments of MOG-CFA/PTX mice at the later
time point (day 15 p.i), further supports previous studies highlighting C3 deficiency inhibits
development of EAE [74].
As to the specific approach used here, i.e., LCM coupled to TLDA, it offered extraordinary
opportunity to probe, in extensive detail, the focused immune response within the distinct CP
compartments. Earlier reports, using immunohistochemistry and in situ hybridization, had
shown that the respective CP stromal capillary endothelial cells and the CP choroidal
epithelial cells displayed different expression patterns of a small nucleus of adhesion

molecules during EAE [4,20]. Specifically, VCAM-1 and ICAM-1 were found to be
expressed constitutively by CP choroidal epithelial cells of healthy SJL/N mice, and then
further induced following active immunization with spinal cord homogenate. MAdCAM-1
was only seen in these cells after induction of EAE. However, none of these adhesion
molecules, nor E- or P-selectin, was detected in CP stromal capillary endothelial cells [75].
We too noted constitutive VCAM-1 expression in the CP choroidal epithelial tissue of
healthy naïve mice. Likewise, VCAM-1 trended toward elevation within this CP
compartment of MOG-CFA/PTX cohorts at both days 9 and 15 p.i., though it showed no upregulation in CFA-PTX-immunized mice at either time-point. In further agreement with
previous observations [75], our analysis demonstrated induction of E-selectin and P-selectin
in the CP choroidal epithelial tissue from MOG-CFA/PTX-immunized mice at day 9. Our
results nevertheless displayed some stark differences with earlier reports. Specifically, we
also noted a trend of increased VCAM-1 expression by day 15 in CP stromal capillary tissue
with MOG immunization, paralleling what has been described in MS brain tissue [6]. And
both E- and P-selectin mRNA were also observed to be induced in CP stromal capillary tissue
of both MOG-CFA/PTX- and CFA/PTX-immunized mice compared to that of naïve mice at
day 9 p.i. E-selectin increased expression in the two immunized groups by >100-fold, while
P-selectin was stimulated >10-fold.
A priori, differences in results between these EAE studies could result from several factors,
among them being 1) the EAE model employed (e.g., immunization of SJL/6 mice with
spinal cord homogenate versus immunization of C57BL/6 mice with MOG35-55 peptide), the
time of analysis post-immunization (e.g, before or after disease onset), and 3) the sensitivity
of the analytic techniques (e.g., in situ hybridization versus qrt-PCR). As neither MAdCAM1 nor ICAM-1 were represented on the TLDA card used in these experiments, confirmation
of expression or lack thereof was not possible for these genes.
Most recently, Liddelow et al. [76] employed LCM to collect mouse lateral ventricular CP
tissue CP for transcriptome analysis of transporter gene expression during normal
development. Here, we extended this application, utilizing LCM to resolve – for the first time
– the CP capillary stromal tissue from the CP choroidal tissue, and then separately analyzing
each for their unique immune responses to MOG immunization.

Conclusions
Induction of EAE in C57BL/6 mice by active immunization with MOG35-55 peptide results in
the respective CP stromal capillary and choroidal epithelial compartments each mounting
vigorous, yet distinct, immune responses, underscoring the active role of the CP in instigating
CNS inflammatory disease. Furthermore, our results make clear that a significant component
of the total CP response is due to effects elicited by adjuvants PTX and/or CFA used in the
immunization protocol – which might serve to prime the CP to support autoimmune activity
necessary for developing MS/EAE. These results are summarized schematically in Figure 6.
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Additional_file_1 as XLS
Additional file 1 Mouse Immune Panel TLDA. The card map for the 96 genes (93 immunerelated genes and 3 control genes) on the commercially available mouse Immune panel
TLDA is shown, with gene names and corresponding accession numbers.

Additional_file_2 as PDF
Additional file 2 Housekeeping control genes. Ct (Threshold cycle) values for the three
housekeeping genes – GAPDH, β-Actin and 18 S represented on the mouse Immune-panel
TLDA are shown. The housekeeping genes were almost unchanged across treatments (shown
in A and B) with < 1 cycle difference between samples. C, Six genes were normalized to each
of the three housekeeping gene and expression patterns plotted, indicating identical patterns
of expression across housekeeping control gene used.
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Additional file 3 Genes that trended towards elevated expression in MOG-CFA/PTXimmunized CP stromal capillary tissue compared to CFA-PTX-immunized mice, at day
15 p.i. Relative mRNA expression values of 93 immune-related genes were determined by
immuno-LCM/TLDA in CP stromal capillary tissue from immunized and naïve mice at day
15 p.i. A total of 14 genes trended towards greater induction in the MOG-CFA/PTX group

compared to the CFA-PTX group; these genes are listed with their corresponding p values.
Analysis was by Student’s two-tailed t-test.
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Additional file 4 Genes similarly up-regulated in CP stromal capillary tissue from both
MOG-CFA/PTX- and CFA-PTX-immunized mice at day 15 p.i. Relative mRNA
expression values of 93 immune-related genes were determined by immuno-LCM/TLDA in
CP stromal capillary tissue from immunized and naïve mice at day 15 p.i. At this later timepoint, 25 immunization-induced genes were similarly stimulated in both MOG-CFA/PTXand CFA-PTX-immunized mice compared to naïve animals, and only these are listed.
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Additional file 5 Genes that trended towards elevated expression in MOG-CFA/PTX
immunized CP epithelium tissue compared to CFA-PTX-immunized mice, at day 9 p.i.
Relative mRNA expression values of 93 immune-related genes were determined by immunoLCM/TLDA in CP epithelium from immunized and naïve mice at day 9 p.i. A total of 15
genes trended towards greater induction in the MOG-CFA/PTX group compared to the CFAPTX group; these genes are listed with their corresponding p values. Analysis was by
Student’s two-tailed t-test.
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Additional file 6 Genes that trended towards elevated expression in MOG-CFA/PTX
immunized CP epithelium tissue compared to CFA-PTX-immunized mice, at day 15 p.i.
Relative mRNA expression values of 93 immune-related genes were determined by immunoLCM/TLDA in CP epithelium from immunized and naïve mice at day 15 p.i. A total of 19
genes trended towards greater induction in the MOG-CFA/PTX group compared to the CFAPTX group; these genes are listed with their corresponding p values. Analysis was by
Student’s two-tailed t-test.
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Additional file 7 Genes similarly up-regulated in CP epithelium from both MOGCFA/PTX- and CFA-PTX-immunized mice at day 9 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/TLDA in CP
epithelium from immunized and naïve mice at day 9 p.i. At this early time-point, 10
immunization-induced genes were similarly stimulated in both MOG-CFA/PTX- and CFAPTX-immunized mice compared to naïve animals, and only these are listed.
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Additional file 8 Genes similarly up-regulated in CP epithelium from both MOGCFA/PTX- and CFA-PTX-immunized mice at day 15 p.i. Relative mRNA expression
values of 93 immune-related genes were determined by immuno-LCM/TLDA in CP
epithelium from immunized and naïve mice at day 15 p.i. At this later time-point, 8
immunization-induced genes were similarly stimulated in both MOG-CFA/PTX- and CFAPTX-immunized mice compared to naïve animals, and only these are listed.
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